| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/11/2001 | WO2001002560A1 Novel genes and their use in the modulation of obesity, diabetes and energy imbalance |
| 01/11/2001 | WO2001002557A1 Neurotrophic factor receptor |
| 01/11/2001 | WO2001002556A2 Agents for the diagnosis, prognosis and treatment of malignant diseases |
| 01/11/2001 | WO2001002550A2 Cell death related drug targets in yeast and fungi |
| 01/11/2001 | WO2001002549A2 Homomeric and heteromeric ampa receptors |
| 01/11/2001 | WO2001002540A2 Adenoviral vectors for treating disease |
| 01/11/2001 | WO2001002439A1 Neovascular-targeted immunoconjugates |
| 01/11/2001 | WO2001002438A1 Means of stabilizing hemoglobins |
| 01/11/2001 | WO2001002437A1 Fibrin citrulline derivatives and their use for diagnosing or treating rheumatoid arthritis |
| 01/11/2001 | WO2001002434A1 Methods for modulating angiogenesis by using the anti-angiogenic angiotensin-7 and polynucleotides encoding therefor |
| 01/11/2001 | WO2001002433A1 Keratinocyte growth factor-2 |
| 01/11/2001 | WO2001002431A1 Recombinant adenovirus |
| 01/11/2001 | WO2001002429A2 Angiopoietin-6 and uses thereof |
| 01/11/2001 | WO2001002427A1 Streptogramin derivatives, preparation and compositions containing them |
| 01/11/2001 | WO2001002426A1 A substantially crystalline form of melagatran |
| 01/11/2001 | WO2001002425A2 Peptide conjugates for the stabilization of membrane proteins and interactions with biological membranes |
| 01/11/2001 | WO2001002424A2 Peptide boronic acid inhibitors of hepatitis c virus protease |
| 01/11/2001 | WO2001002420A1 PURIFIED AND ISOLATED MAT II β SUBUNIT NUCLEIC ACIDS AND POLYPEPTIDES AND THERAPEUTIC AND SCREENING METHODS USING SAME |
| 01/11/2001 | WO2001002405A1 Quinuclidine derivatives for treatment of neurological disorders |
| 01/11/2001 | WO2001002376A1 Amino-alkyl derivatives |
| 01/11/2001 | WO2001002372A1 Cyclized amino acid derivatives |
| 01/11/2001 | WO2001002368A1 N-heterocyclic derivatives with neuronal activity |
| 01/11/2001 | WO2001002363A2 N-substituted glycine derivatives |
| 01/11/2001 | WO2001002362A1 Azo amino acid derivatives for the treatment of neurological diseases |
| 01/11/2001 | WO2001002358A2 Cyclized amide derivatives for treating or preventing neuronal damage |
| 01/11/2001 | WO2001002029A1 Agent for occluding blood vessels |
| 01/11/2001 | WO2001002019A2 Control of gene expression |
| 01/11/2001 | WO2001002017A2 Erythropoietin conjugates with polyethylenglycol |
| 01/11/2001 | WO2001002012A1 Remedies for drug-resistant hypercalcemia |
| 01/11/2001 | WO2001002006A2 Fertility impairing vaccine containing avian zona pellucida protein and method of use |
| 01/11/2001 | WO2001002004A1 Peritoneal dialysis solution containing antioxidant for treating renal failure |
| 01/11/2001 | WO2001002003A1 Method of treating psoriasis with il-15 antagonist |
| 01/11/2001 | WO2001002002A1 Stabilized pharmaceutical composition in lyophilized form |
| 01/11/2001 | WO2001002001A1 PEPTIDE LIGANDS THAT BIND IgM ANTIBODIES AND BLOCK INTERACTION WITH ANTIGEN |
| 01/11/2001 | WO2001002000A2 Method and composition for affecting reproductive systems |
| 01/11/2001 | WO2001001999A1 Method of inducing apoptosis in b-lymphocytes |
| 01/11/2001 | WO2001001998A2 Treatment of endometriosis with antileukoprotease |
| 01/11/2001 | WO2001001997A1 Medicaments comprising relaxin and their use |
| 01/11/2001 | WO2001001965A1 Grf-containing lyophilized pharmaceutical compositions |
| 01/11/2001 | WO2001001922A2 Use of substance p antagonists for the treatment of adenocarcinoma |
| 01/11/2001 | WO2001001921A1 Preserving a hemoglobin blood substitute with a transparent overwrap |
| 01/11/2001 | WO2001001786A2 Methods and means for producing improved dairy products |
| 01/11/2001 | WO2001001775A1 Preserving a hemoglobin blood substitute with a transparent overwrap |
| 01/11/2001 | WO2001001749A2 FVIIa ANTAGONISTS |
| 01/11/2001 | WO2001001748A2 Peptide compounds that bind her2 |
| 01/11/2001 | WO2000066707A8 Novel thiamine transporter, a polynucleotide encoding same and their uses |
| 01/11/2001 | WO2000063364A3 Methods and compositions for inhibiting the function of polynucleotide sequences |
| 01/11/2001 | WO2000062657A3 Improvement of t cell mediated immunity |
| 01/11/2001 | WO2000061793A3 Novel method for identifying antibacterial compounds |
| 01/11/2001 | WO2000061747A3 Clasp-2 transmembrane proteins |
| 01/11/2001 | WO2000061608A3 Low-molecular inhibitors of complement proteases |
| 01/11/2001 | WO2000061189A3 Water-soluble compositions of bioactive lipophilic compounds |
| 01/11/2001 | WO2000061167A3 TREATMENT OF MYELOMA BONE DISEASE WITH PROTEASOMAL AND NF-λB ACTIVITY INHIBITORS |
| 01/11/2001 | WO2000059515A3 Immunomodulating polymers |
| 01/11/2001 | WO2000059485A3 Pharmaceutical compositions comprising in combination a bisphosphonate and a matrix metalloproteinase inhibitor |
| 01/11/2001 | WO2000058466A3 Protease resistant flint analogs |
| 01/11/2001 | WO2000056351A3 Combination use of gemcitabine and tumor suppressor gene therapy in the treatment of neoplasms |
| 01/11/2001 | WO2000056345A3 Methods for limiting scar and adhesion formation |
| 01/11/2001 | WO2000054770A8 Pharmaceutical compositions comprising troponin subunits, fragments and homologs thereof and methods of their use to inhibit angiogenesis |
| 01/11/2001 | WO2000053748A3 Casb618 polynucleotides and polypeptides and their use |
| 01/11/2001 | WO2000053738A3 Methods and compositions for regulating memory consolidation |
| 01/11/2001 | WO2000053217A3 Prevention of fetal alcohol syndrome and neuronal cell death with adnf polypeptides |
| 01/11/2001 | WO2000053216A3 Use of casb616 polypeptides and polynucleotides for cancer treatment |
| 01/11/2001 | WO2000052154A3 Methods and reagents for decreasing clinical reaction to allergy |
| 01/11/2001 | WO2000052034A3 Inhibitors of serine protease activity, methods and compositions for treatment of viral infections |
| 01/11/2001 | WO2000047622A3 Peptides with anti-angiogenic activity |
| 01/11/2001 | WO2000044397A3 Growth of inner ear and monoclonal antibody against utricular epithelium |
| 01/11/2001 | WO2000040273A8 Treatment of viral diseases using an interferon omega expressing polynucleotide |
| 01/11/2001 | WO2000039278A8 Pth functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules |
| 01/11/2001 | WO2000037679A3 Method for determining the susceptibility to developing sepsis and therapeutics for the treatment of sepsis |
| 01/11/2001 | WO2000029012A8 Methods of alleviating cancer symptoms |
| 01/11/2001 | DE19931883A1 DNA kodierend für Beta-Tubulin und deren Verwendung DNA coding for beta-tubulin, and the use thereof |
| 01/11/2001 | DE19930512A1 New human N-formyl receptor gene, useful for diagnosis and treatment of disease |
| 01/11/2001 | DE19929887A1 cDNA-Sequenzen von zwei Interakoren FANCIP2 und FANCIP3 des Fanconi-Anämie-Proteins der Komplementationsgruppe A cDNA sequences of two Interakoren FANCIP2 and FANCIP3 of the Fanconi anemia complementation group A-protein of the |
| 01/11/2001 | CA2399045A1 Keratinocyte growth factor-2 |
| 01/11/2001 | CA2383943A1 Snail, a new marker for tumour invasion and target protein of new antitumoral compounds |
| 01/11/2001 | CA2380875A1 Cell death related drug targets in yeast and fungi |
| 01/11/2001 | CA2378951A1 Secreted protein zacrp4 |
| 01/11/2001 | CA2378606A1 Agent for occluding blood vessels |
| 01/11/2001 | CA2378598A1 Medicaments comprising relaxin and their use |
| 01/11/2001 | CA2378478A1 Fertility impairing vaccine containing avian zona pellucida protein and method of use |
| 01/11/2001 | CA2378472A1 Method and composition for affecting reproductive systems |
| 01/11/2001 | CA2378324A1 Recombinant adenovirus |
| 01/11/2001 | CA2378153A1 Global regulators of bacterial pathogenic genes; bacterial autoinducer inactivation protein, as targets for engineering disease resistance |
| 01/11/2001 | CA2378116A1 Human immune response molecules |
| 01/11/2001 | CA2377931A1 Novel mammalian calcium channels and related probes, cell lines and methods |
| 01/11/2001 | CA2377822A1 Means of stabilizing hemoglobin |
| 01/11/2001 | CA2377795A1 Use of the krit1 gene in angiogenesis |
| 01/11/2001 | CA2377791A1 Novel polypeptide and dna thereof |
| 01/11/2001 | CA2377788A1 Methods for modulating angiogenesis by using the anti-angiogenic angiotensin-7 and polynucleotides encoding therefor |
| 01/11/2001 | CA2377784A1 Novel genes and their use in the modulation of obesity, diabetes and energy imbalance |
| 01/11/2001 | CA2377381A1 Neovascular-targeted immunoconjugates |
| 01/11/2001 | CA2377107A1 Delivery of trefoil peptides |
| 01/11/2001 | CA2376965A1 Peptide boronic acid inhibitors of hepatitis c virus protease |
| 01/11/2001 | CA2376944A1 A substantially crystalline form of melagatran |
| 01/11/2001 | CA2376698A1 Streptogramin derivatives, preparation and compositions containing them |
| 01/11/2001 | CA2376513A1 An interleukin-1 receptor antagonist and uses thereof |
| 01/11/2001 | CA2376166A1 Control of gene expression |
| 01/11/2001 | CA2374033A1 Preserving a hemoglobin blood substitute with a transparent overwrap |
| 01/11/2001 | CA2373960A1 Use of substance p antagonists for the treatment of adenocarcinoma |